ClinicalTrials.Veeva

Menu

Esophageal Injury of a Tip CF Sensing Ablation Catheter for HP-SD of Paroxysmal and Persistent AF (ESO-SAFE-HP-RF)

Q

Quovadis Associazione

Status

Enrolling

Conditions

Esophageal Perforation
Atrial Fibrillation
Esophageal Fistula

Treatments

Device: mini-invasive esophagoscopy
Device: HP-SD AF ablation by a CF sensing catheter

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05758805
ESO-SAFE-HP-RF Study

Details and patient eligibility

About

This pilot, prospective, interventional, monocentric, independent, and no-profit clinical trial aims to investigate and evaluate the proportion, acute and chronic characteristics, and outcomes of esophageal thermal injury (ETI) in AF ablation using a high-power, short-duration (HP-SD) setting with contact force (CF) sensing tip ablation catheter in standard clinical practice. The main questions it aims to answer are:

  • Evaluate the acute proportion of the ETI assessed by the mini-invasive esophagoscopy pre and post-procedure. In addition, clinical evaluations at 3, 6, and 12 months from the procedure are foreseen.
  • Evaluate the contribution of the factors influencing RF procedure (contact force, impedance, RF power, RF time) on ETI development.
  • Describe the relationship between the esophageal temperature (continuous monitoring) and ETI development.

Full description

This study aims to estimate the proportion of esophageal thermal injury (ETI) as a result of the AF ablation using a high-power, short-duration (HP-SD) setting with contact force (CF) sensing tip ablation catheter immediately after and at 3, 6, and 12 months from the procedure, as well as describe their characteristics.

To be more sensitive and specific in detecting the presence of potentially chronic and progressing ETIs in esophageal ulcers and atrium-esophageal fistula, a minimally invasive esophagogastroscope will be used before (1-7 days) and after (1-3 days) the ablation procedure, with an internal comparison of the lesions observed. In addition, various clinical characteristics of the patients and descriptors of the ablation procedure (such as contact force, impedance, RF power, RF time, esophageal temperature, procedure times, etc.) will be collected and related to the presence of ETI.

The principal Medical Devices that will be used:

  1. Cardiac Mapping system Ensite X (Abbott Medical),
  2. Tip CF sensing catheter TactiFlex (Abbott Medical),
  3. High mapping density catheter (HD GRID/Advisor FL, Abbott Medical),
  4. Continuous temperature monitoring devices (Esotest Multi/Esotherm 7 poles, FIAB),
  5. Video-endoscope EXERA III HDTV dual focus GIF-HQ190 (Olympus).

Enrollment

51 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Atrial fibrillation and, according to current guidelines, indication for radiofrequency ablation guided by electro-anatomical mapping with high-density mapping catheter and radiofrequency ablation by contact force ablation catheter.
  2. Able to sign the consent form.

Exclusion criteria

  1. LVEF < 45%
  2. Presence of thrombus in the left atrium
  3. NYHA III/IV Class
  4. Atrial diameter > 50mm
  5. Moderate or severe valve dysfunction
  6. Implanted ICD/CRT-D
  7. Life expectancy < 1 year
  8. Uncontrolled Hyperthyroidism
  9. Hypertrophic or dilatative cardiomyopathy
  10. Kidney failure (eGFR < 30)
  11. Body Mass Index (BMI)> or = 35
  12. Participation in another clinical trial in the past 3 months
  13. Inability to express informed consent for the study
  14. Patients with esophageal pathologies and a history of gastritis
  15. Pregnancy (ascertained by performing the HCG test), breastfeeding, pregnancy planned during the study, or fertile female subjects who refused to use a highly effective contraceptive measure.

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

51 participants in 1 patient group

Unique Arm
Experimental group
Description:
patients with atrial fibrillation and indication for radiofrequency ablation guided by electro-anatomical mapping with high-density mapping catheter and radiofrequency ablation by contact force ablation catheter, according to current guidelines
Treatment:
Device: HP-SD AF ablation by a CF sensing catheter
Device: mini-invasive esophagoscopy

Trial contacts and locations

1

Loading...

Central trial contact

Antonio Dello Russo, MD; Franco Noventa, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems